Niquitin Minizuigtablet (Nicotine)

Nicotine, the active ingredient in Niquitin Minizuigtablet, is a Nicotinic receptor agonist presented as a tablet for Oromucosal use. It is used to aid smoking cessation in adults who wish to quit tobacco dependence.

GNH USA supplies Niquitin Minizuigtablet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Niquitin Minizuigtablet is a nicotinic receptor agonist indicated for conditions related to tobacco use and nicotine dependence.

- Smoking cessation: helps reduce withdrawal symptoms and cravings in adults attempting to quit tobacco. - Nicotine dependence: supports gradual reduction of nicotine intake during a quit attempt. - Relapse prevention: assists in maintaining abstinence after initial quitting.

Adverse reactions may occur with use of Niquitin Minizuigtablet.

Common Side Effects: - Mouth irritation or soreness. - Nausea or upset stomach. - Headache. - Dizziness. - Insomnia or sleep disturbances. - Unpleasant taste.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Chest pain or palpitations. - Hypertension or significant blood pressure rise. - Cardiac arrhythmias. - Seizures. - Stevens‑Johnson syndrome or other severe skin reactions.

Before prescribing Niquitin Minizuigtablet, clinicians should consider several safety aspects.

- Assess nicotine dependence level: evaluate the patient’s smoking history and readiness to quit. - Avoid use in recent myocardial infarction: consider cardiovascular risk before initiation. - Monitor blood pressure: nicotine can elevate systolic and diastolic pressures. - Do not combine with other nicotine replacement products without medical guidance: risk of nicotine overdose. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Niquitin Minizuigtablet may interact with other medicines; some interactions require avoidance while others need monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis. - CYP2A6 inhibitors: may raise nicotine plasma concentrations. - Other nicotine replacement therapies: risk of nicotine overdose.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may increase nausea. - Antihypertensive agents: nicotine may reduce their efficacy. - Theophylline: nicotine may increase its metabolism, altering therapeutic levels.